{"id":"exp-1-data-minimalism","title":"Data Minimalism vs. Data Maximalism for Rare Disease Drug Repurposing","assumption":"Data Maximalism Assumption - more comprehensive multi-modal datasets always improve repurposing predictions","hypothesis":"H1: Minimal but highly curated datasets achieve superior actionable predictions compared to comprehensive multi-modal approaches","evaluationPlan":"AI agent automated pipeline: (1) Download and preprocess DrugBank, ChEMBL, OMIM, GTEx datasets, (2) Train comprehensive model with >10K features vs minimal model with <500 curated features, (3) Automated evaluation on 50 rare diseases with known outcomes, (4) Statistical significance testing with automated early stopping if minimal approach fails on >80% of diseases","implications":"Could unlock repurposing for ultra-rare conditions with extremely limited data and establish data quality over quantity principles for all biomedical AI","relatedWork":"Drug repurposing studies using multi-modal integration, feature selection for biomedical prediction, clinical actionability in AI systems","milestones":"Week 2: Automated data pipelines complete, Week 8: Parallel model training complete, Week 10: Comprehensive evaluation complete, Week 12: Statistical analysis and assumption validation complete","successCriteria":"Strong: >20% better actionable accuracy (p<0.01), Moderate: >10% improvement (p<0.05), Failure triggers automated investigation of data quality thresholds","priority":"high","status":"proposed","notes":"Foundation experiment with automated vectoring - highest risk assumption that could invalidate entire minimalist approach","aiExecutable":"true","vectoringRisk":"highest","automationProtocol":"Fully automated data pipelines, model training, evaluation, and statistical analysis with real-time early stopping rules","createdDate":"2025-08-13T05:22:16Z"}
{"id":"exp-2-actionability-first","title":"Actionability-First vs. Accuracy-First AI Design","assumption":"Accuracy-First Assumption - predictive accuracy is the primary success metric for AI systems","hypothesis":"H2: Models designed for clinical actionability (interpretability, uncertainty quantification, decision support) outperform accuracy-optimized models in clinical outcomes","evaluationPlan":"Retrospective analysis of clinical decision-making with 100 rare disease cases. Compare traditional accuracy-optimized models vs. actionability-optimized models with interpretability and uncertainty quantification. Measure clinical adoption rate, patient outcomes, and physician confidence.","implications":"Could bridge the gap between AI predictions and clinical implementation, establishing new evaluation standards for medical AI","relatedWork":"Explainable AI in healthcare, clinical decision support systems, uncertainty quantification in medical prediction","milestones":"Week 8: Model development complete, Week 14: Clinical evaluation complete, Week 16: Analysis complete","successCriteria":"Clinical adoption rate >40% higher, patient outcomes >20% improvement, physician confidence >30% higher","priority":"high","status":"proposed","notes":"Critical for clinical translation - tests whether accuracy is the right optimization target","createdDate":"2025-08-13T05:22:16Z"}
{"id":"exp-3-cross-disease-transfer","title":"Cross-Disease Transfer Learning vs. Disease-Specific Models","assumption":"Disease-Specific Modeling Assumption - each rare disease requires custom computational approaches","hypothesis":"H3: Transfer learning models leveraging shared mechanistic patterns outperform disease-specific models, especially for ultra-rare conditions with limited data","evaluationPlan":"Compare disease-specific models vs. meta-learning models across three data availability scenarios: high-data (>1000 patients), low-data (100-999 patients), and ultra-rare (<100 patients). Evaluate prediction accuracy, generalization, and training efficiency.","implications":"Could enable repurposing for diseases with insufficient individual datasets by leveraging cross-disease patterns","relatedWork":"Transfer learning in biomedical domains, meta-learning for few-shot prediction, cross-disease analysis","milestones":"Week 12: Model development complete, Week 18: Evaluation complete, Week 20: Analysis complete","successCriteria":"Ultra-rare disease accuracy improvement >35%, generalization score >0.75, training efficiency >50% improvement","priority":"high","status":"proposed","notes":"Key for scaling to ultra-rare diseases with minimal data","createdDate":"2025-08-13T05:22:16Z"}
{"id":"exp-4-parallel-validation","title":"Parallel vs. Sequential Validation Strategies","assumption":"Sequential Validation Assumption - drug validation must follow linear preclinical → clinical stages","hypothesis":"H4: Parallel multi-stage validation using real-world evidence achieves equivalent safety validation in significantly less time","evaluationPlan":"Retrospective analysis of historical drug repurposing cases comparing traditional sequential validation vs. parallel validation using real-world evidence and computational modeling. Measure time-to-decision, safety signal detection, and resource efficiency.","implications":"Could dramatically reduce time-to-treatment for rare disease patients while maintaining safety standards","relatedWork":"Real-world evidence in drug development, regulatory science, accelerated approval pathways","milestones":"Week 16: Protocol development complete, Week 22: Retrospective analysis complete, Week 24: Reporting complete","successCriteria":"Time reduction >60% while maintaining safety, safety signal detection ≥95% of sequential method, resource efficiency >40%","priority":"medium","status":"proposed","notes":"Tests regulatory pathway assumptions - requires partnership with regulatory scientists","createdDate":"2025-08-13T05:22:16Z"}
{"id":"exp-5-human-ai-collaboration","title":"Human-AI Collaboration vs. Fully Automated Systems","assumption":"AI Supremacy Assumption - AI should minimize human bias and replace expert judgment","hypothesis":"H5: Collaborative human-AI systems leveraging irreplaceable rare disease expertise outperform fully automated approaches for complex repurposing decisions","evaluationPlan":"AI agent simulation: (1) Build fully automated repurposing system, (2) Implement human-AI collaborative interface with expert simulation, (3) Automated A/B testing across 200 drug repurposing cases with known ground truth, (4) Categorize decisions by complexity and measure quality differences","implications":"Could leverage irreplaceable rare disease expertise while scaling discovery, establishing optimal human-AI collaboration models","relatedWork":"Human-AI collaboration, clinical decision support, expert systems in medicine","milestones":"Week 4: Automated and collaborative systems complete, Week 12: Comparative evaluation complete, Week 16: Decision complexity analysis complete, Week 18: Collaboration optimization complete","successCriteria":"Strong: >35% better decision quality on complex cases, Moderate: >20% improvement with acceptable efficiency, Failure triggers investigation of AI capability limits","priority":"medium","status":"proposed","notes":"Tests fundamental assumption about AI replacing vs. amplifying human expertise - uses expert simulation for AI agent execution","aiExecutable":"true","vectoringRisk":"medium","automationProtocol":"Expert simulation based on clinical decision patterns, automated A/B testing, real-time performance monitoring","createdDate":"2025-08-13T05:22:16Z"}
{"id":"micro-exp-b-actionability-ablation","title":"Actionability Feature Ablation Study","assumption":"Unclear which actionability features contribute most to clinical utility","hypothesis":"Specific actionability features (interpretability vs uncertainty vs decision support) have differential impacts on clinical outcomes","evaluationPlan":"Automated ablation study systematically removing actionability features and measuring clinical utility scores. Test interpretability (SHAP/LIME), uncertainty quantification, and decision support features independently.","implications":"Optimizes actionability feature selection to maximize clinical utility while minimizing computational overhead","relatedWork":"Ablation studies in explainable AI, clinical utility measurement, feature importance analysis","milestones":"Day 1: Baseline actionable model, Day 2: Automated ablation testing, Day 3: Feature importance ranking","successCriteria":"Rank actionability features by clinical utility contribution and identify minimum viable feature set","priority":"medium","status":"proposed","notes":"Fast identification of most important actionability features for clinical AI systems","aiExecutable":"true","vectoringRisk":"low","automationProtocol":"Automated feature ablation with clinical utility scoring","timelineWeeks":"0.5","createdDate":"2025-08-13T05:39:45Z"}